Ashley Gallagher, MA

With the acceptance of the new drug application and granting priority review, the target action date is August 12, 2025.

App notifications can be effected by various notification focuses, software updates, or connecting hardware, such as car audio or wireless earphones.

The prevalence of high blood pressure is highest in Mississippi at 40.2% compared with the lowest in Colorado at 24.6%.

ADI-001 is an investigation allogeneic gamma delta chimeric antigen receptor T cell therapy that targets CD20 for the treatment of a variety of autoimmune diseases.

Primary hyperoxaluria type 1 (PH1) is a rare genetic condition that affects the kidney, bladder, or urinary tract, and indicates high levels of oxalates in the urine.

Investigators also find that the proportion of patients that were admitted to the intensive care unit after hospital admission was much higher for Black rural patients.

The therapy is now the first and only FDA-approved treatment that maintains vision with fewer treatments compared to standard-of-care injections.

Sodium-glucose cotransporter 2 inhibitors are more cardioprotective in older adults and glucagon-like peptide-1 receptor agonists for younger patients.

The drug will be made available in the second quarter of 2025.

Approximately 29% of patients were also more likely to refill their medication, leading investigators to consider an association between medication adherence.

In a phase 1b/2a clinical trial, investigators evaluated the once weekly subcutaneous drug for safety, tolerability, pharmacokinetics, and proof-of-concept.

Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed current GLP-1 medication offerings and how each impacts patients differently.

Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed the benefits of tirzepatide compared with semaglutide.

A conversation with Chelsea Keedy, PharmD, BCACP, clinical assistant professor at the University of Georgia, on RSV vaccine recommendations.

Drug Topics met with Lourdes Cross, PharmD, BCACP, CDCES, to discuss pharmacists’ role in managing patients’ chronic obstructive pulmonary disease.

Drug Topics met with Amanuel Kehasse, PharmD, PhD, to discuss the barriers surrounding biosimilar implementation in the prescription drug market.

Denise Kelley, PharmD, BCPS, FASHP, joined Drug Topics to discuss various medications for chronic kidney disease and their common adverse reactions.

Kathryn Litten, PharmD, discussed the pharmacist’s role in helping patients manage metabolic dysfunction-associated steatotic liver disease.

A conversation with Julia L. Ziegengeist, PharmD, BCOP, clinical pharmacist coordinator of breast medical oncology for the Levine Cancer Institute at Atrium Health.

Lourdes Cross, PharmD, BCACP, CDCES, discussed chronic obstructive pulmonary disease and how pharmacists are positioned to help patients’ exacerbations.

A conversation with Chelsea Keedy, PharmD, BCACP, clinical assistant professor at the University of Georgia.

Amanuel Kehasse, PharmD, PhD, explored reasons why patients and providers may be avoiding the implementation of biosimilar medications.

Ethan Melillo, PharmD, CDOE, senior manager of Integrated Health at L’Oréal, provides some of his favorite recommendations to help with irritated skin.

John Bucheit, PharmD, joined Drug Topics to discuss statins and nonstatins’ efficacy in treating cardiovascular disease.

Denise Kelley, PharmD, BCPS, FASHP, discussed the efficacy of medications designed to treat the progression of chronic kidney disease.

A conversation with Kathleen Vest, PharmD, BCACP, CDCES, FCCP, professor of Pharmacy Practice at Drake University College of Pharmacy and Health Sciences.

Kathryn Litten, PharmD, joined Drug Topics to discuss how pharmacists can counsel patients with metabolic dysfunction-associated steatotic liver disease.

A discussion with Kevin Cowart, PharmD, MPH, BCACP, FCCP, BCPS, assistant professor at the University of South Florida Taneja College of Pharmacy.

John Bucheit, PharmD, discussed lipid-lowering medications and how nonstatins can be beneficial for cardiovascular health.

A discussion with Brittany Norton, PharmD, director of ambulatory care at Sutter Health.